Bayer spin-off AiCuris (Wuppertal, Germany) has acquired exclusive rights to develop and commercialize RNA-based therapies for individuals with acute and chronic kidney diseases. AiCuris will acquire the developmental therapies from the startup Hybridize Therapeutics (Leiden, Netherlands), which will get €100 million in upfront and milestone payments in addition to tiered royalties on net sales. Sitting…